Anticoagulants and their reversal

被引:136
作者
Schulman, Sam
Bijsterveld, Nick R.
机构
[1] McMaster Univ, Dept Med, Hamilton, ON, Canada
[2] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands
关键词
D O I
10.1016/j.tmrv.2006.08.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In an exciting era with many alternatives to the old anticoagulants heparin and warfarin emerging on the scene, awareness of the possibility to reverse their effect is mandatory. In this review, the traditional antidotes for warfarin (vitamin K, plasma, and prothrombin complex concentrate) and for heparin (protamine) are described together with the newer alternatives (recombinant activated factor VII, concatameric peptides, and recombinant platelet factor 4). For some of the newer anticoagulants, possible antidotes have been identified, whereas other alternatives have been discarded. There is a very limited experience of deamino-D-arginine vasopressin or a von Willebrand factor VIII concentrate to counteract hirudin. The small direct thrombin inhibitors may be reversed with activated prothrombin complex concentrate but not with recombinant activated factor VII, whereas the latter agent appears to be effective against the pentasaccharides and the recombinant nematode anticoagulant protein C2. Additional options that may become available in the future are also discussed briefly. (c) 2007 Elsevier Inc. All rights reserved
引用
收藏
页码:37 / 48
页数:12
相关论文
共 51 条
[1]   Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VII inhibitor bypass activity [J].
Aledort, LM .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (10) :1700-1708
[2]   The pharmacology and management of the vitamin K antagonists [J].
Ansell, J ;
Hirsh, J ;
Poller, L ;
Bussey, H ;
Jacobson, A ;
Hylek, E .
CHEST, 2004, 126 (03) :204S-233S
[3]   Guidelines on oral anticoagulation (warfarin): third edition - 2005 update [J].
Baglin, TP ;
Keeling, DM ;
Watson, HG .
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 132 (03) :277-285
[4]   Nucleic acid aptamers in therapeutic anticoagulation - Technology, development and clinical application [J].
Becker, RC ;
Rusconi, C ;
Sullenger, B .
THROMBOSIS AND HAEMOSTASIS, 2005, 93 (06) :1014-1020
[5]   Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers [J].
Bijsterveld, NR ;
Vink, R ;
van Aken, BE ;
Fennema, H ;
Peters, RJG ;
Meijers, JCM ;
Büller, HR ;
Levi, M .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 124 (05) :653-658
[6]   The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes [J].
Bijsterveld, NR ;
Moons, AH ;
Meijers, JCM ;
Levi, M ;
Büller, HR ;
Peters, RJG .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (03) :424-427
[7]  
Bove CM, 1996, THROMB HAEMOSTASIS, V75, P471
[8]   Fondaparinux or Enoxaparin for the initial treatment of symptomatic deep venous thrombosis -: A randomized trial [J].
Büller, HR ;
Davidson, BL ;
Decousus, H ;
Gallus, A ;
Gent, M ;
Piovella, F ;
Prins, MH ;
Raskob, G ;
Segers, AEM ;
Cariou, R ;
Leeuwenkamp, O ;
Lensing, AWA .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (11) :867-873
[9]  
Buller HR, 2004, J THROMB HAEMOST, V2, P47
[10]  
Büller HR, 2003, NEW ENGL J MED, V349, P1695